Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.
Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J. Ziol M, et al. Among authors: bouattour m. Hepatology. 2018 Jul;68(1):103-112. doi: 10.1002/hep.29762. Epub 2018 May 9. Hepatology. 2018. PMID: 29281854
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Among authors: bouattour m. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Free article. Clinical Trial.
[Targeted therapies in hepatocellular carcinoma].
Bouattour M, Marijon H, Dreyer C, Faivre S, Raymond E. Bouattour M, et al. Presse Med. 2010 Jul-Aug;39(7-8):753-64. doi: 10.1016/j.lpm.2009.11.016. Epub 2010 Apr 7. Presse Med. 2010. PMID: 20378303 French.
Novel molecular therapies in hepatocellular carcinoma.
Faivre S, Bouattour M, Raymond E. Faivre S, et al. Among authors: bouattour m. Liver Int. 2011 Jan;31 Suppl 1:151-60. doi: 10.1111/j.1478-3231.2010.02395.x. Liver Int. 2011. PMID: 21205154 Review.
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E. Faivre S, et al. Among authors: bouattour m. Clin Cancer Res. 2011 Jul 1;17(13):4504-12. doi: 10.1158/1078-0432.CCR-10-1708. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531821 Clinical Trial.
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Ronot M, et al. Among authors: bouattour m. Oncologist. 2014 Apr;19(4):394-402. doi: 10.1634/theoncologist.2013-0114. Epub 2014 Mar 20. Oncologist. 2014. PMID: 24652387 Free PMC article.
95 results